Cyclacel Pharmaceuticals Files 8-K on Shareholder Votes & Financials
Ticker: BGMSP · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1130166
Sentiment: neutral
Topics: 8-K, corporate-governance, financial-reporting
Related Tickers: CYCC
TL;DR
Cyclacel filed an 8-K on Sep 5th covering shareholder votes and financials. Check it out.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 5, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing pertains to the company's operations as of September 4, 2025. The company, formerly Xcyte Therapies Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
This filing provides updates on key corporate actions and financial reporting, which are crucial for investors to assess the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on standard corporate events and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former Company Name
- September 4, 2025 (date) — Earliest event reported
- September 5, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that 'Submission of Matters to a Vote of Security Holders' is an item reported, but the specific details of these matters are not provided in the excerpt.
What financial statements are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in the provided text.
When was the company formerly known as?
The company was formerly known as XCYTE THERAPIES INC.
In which state is Cyclacel Pharmaceuticals, Inc. incorporated?
Cyclacel Pharmaceuticals, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification code for Cyclacel Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Cyclacel Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-09-05 11:53:14
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 45KB
- form8-k_001.jpg (GRAPHIC) — 5KB
- 0001641172-25-026676.txt ( ) — 267KB
- cycc-20250904.xsd (EX-101.SCH) — 4KB
- cycc-20250904_def.xml (EX-101.DEF) — 26KB
- cycc-20250904_lab.xml (EX-101.LAB) — 36KB
- cycc-20250904_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 5, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director